metaMe Health develops Prescription Digital Therapeutics (PDT) for treating common chronic conditions, starting with gastrointestinal disorders. Its flagship app, Regulora, is a non-drug option for treating abdominal pain associated with irritable bowel syndrome (IBS) in adults and allows individuals to undergo treatment at home. The prescription-based treatment will be available in 2H 2022 via healthcare providers and health plans.
The company says Regulora is the first PDT to receive 510(k) approval for treating pain related to IBS. The app delivers self-administered Gut-Directed Hypnotherapy (GDH) to relieve IBS pain and can be used together with other IBS treatments. The app-based treatment includes 30-minute hypnotherapy sessions and additional practice sessions over a period of 12 weeks. The company also says it is the first digital solution to offer GDH virtually as the treatment was only available in person previously. metaMe partnered with Indegene to help launch Regulora by leveraging Indegene’s co-commercialization model to market its PDT to healthcare providers, patients, and insurance providers.
Its latest funding round took place in March 2022, when it raised USD 2.2 million in a bridge funding round led by Hyde Park Angels which will be used for the commercial launch of Regulora and to enhance its infrastructure.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.